These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26079148)

  • 1. Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.
    Casi G; Neri D
    J Med Chem; 2015 Nov; 58(22):8751-61. PubMed ID: 26079148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninternalizing targeted cytotoxics for cancer therapy.
    Casi G; Neri D
    Mol Pharm; 2015 Jun; 12(6):1880-4. PubMed ID: 25738312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
    Papachristos A; Pippa N; Demetzos C; Sivolapenko G
    Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates: Current status and future perspectives.
    Gébleux R; Casi G
    Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in tumor-targeting anticancer drug conjugates.
    Jaracz S; Chen J; Kuznetsova LV; Ojima I
    Bioorg Med Chem; 2005 Sep; 13(17):5043-54. PubMed ID: 15955702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
    Wolska-Washer A; Robak T
    Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
    Jackson D; Stover D
    Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor specific novel taxoid-monoclonal antibody conjugates.
    Wu X; Ojima I
    Curr Med Chem; 2004 Feb; 11(4):429-38. PubMed ID: 14965224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of bioconjugate therapeutics: why, when, and how?
    Liu H; Bolleddula J; Nichols A; Tang L; Zhao Z; Prakash C
    Drug Metab Rev; 2020 Feb; 52(1):66-124. PubMed ID: 32045530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell killing by antibody-drug conjugates.
    Kovtun YV; Goldmacher VS
    Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery.
    Casi G; Huguenin-Dezot N; Zuberbühler K; Scheuermann J; Neri D
    J Am Chem Soc; 2012 Apr; 134(13):5887-92. PubMed ID: 22394212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.
    Wilson R
    Bioanalysis; 2013 May; 5(9):1083-97. PubMed ID: 23641698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small targeted cytotoxics from DNA-encoded chemical libraries.
    Samain F; Casi G
    Curr Opin Chem Biol; 2015 Jun; 26():72-9. PubMed ID: 25726911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
    Okeley NM; Alley SC; Senter PD
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):13-25. PubMed ID: 24287064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interview with the Theme Issue Editors of Antibody-Drug Conjugates.
    Kulkarni A; Gukasyan H
    Pharm Res; 2015 Nov; 32(11):3453-7. PubMed ID: 26337768
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal antibody-based therapies in cancer: advances and challenges.
    Sapra P; Shor B
    Pharmacol Ther; 2013 Jun; 138(3):452-69. PubMed ID: 23507041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.